GlassScriptPhysician profile
Stephen O Slusser
NPI 1003880006
$2,926.02
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $388 · 2021: $506 · 2022: $826 · 2023: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $792.09 | 2019-2023 | Linzess, Viberzi, Rinvoq |
| Janssen Biotech, INC. | $401.79 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $394.55 | 2019-2023 | Entyvio |
| Ferring Pharmaceuticals INC. | $307.14 | 2019-2023 | Rebyota |
| Celgene Corporation | $190.42 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $145.43 | 2019-2023 | Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.85 | 2019-2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $85.90 | 2020-2023 | Ocaliva |
| Ardelyx, INC. | $84.41 | 2022-2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $75.50 | 2021-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $74.53 | 2022-2023 | Linzess |
| Ucb, INC. | $71.95 | 2019-2020 | |
| Blueprint Medicines Corporation | $36.31 | 2023 | |
| Echosens North America, INC. | $34.54 | 2019 | |
| Pfizer INC. | $23.05 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $17.92 | 2023 | Axonics |
| Medtronic, INC. | $16.19 | 2021 | |
| Sebela Pharmaceuticals INC. | $16.11 | 2023 | Sutab |
| Nestle Healthcare Nutrition INC. | $12.41 | 2022 | |
| Novo Nordisk INC | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Slusser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.